Core Viewpoint - Pfizer (PFE.US) shares fell over 4% to $25.27 as the company forecasts minimal or no sales growth for the upcoming year due to expensive acquisitions aimed at updating its popular drug lineup [1] Financial Projections - Pfizer expects revenue for 2026 to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] - The company anticipates this year's sales to reach $62 billion, consistent with its guidance from early November [1] - Adjusted earnings per share for next year are projected to be between $2.80 and $3.00 [1] Market Challenges - CEO Albert Bourla faces a critical moment in revitalizing Pfizer as demand for COVID-19 vaccines and treatments, which previously drove sales growth, is declining [1] - Revenue from COVID-related products is expected to decrease by approximately $1.5 billion to $5 billion next year [1]
美股异动 | 辉瑞(PFE.US)跌逾4% 公司预计2026年营收增长将放缓